Hemostemix Inc. (CVE:HEM – Get Free Report) fell 17.1% on Thursday . The stock traded as low as C$0.28 and last traded at C$0.32. 684,632 shares were traded during trading, an increase of 2% from the average session volume of 673,865 shares. The stock had previously closed at C$0.38.
Hemostemix Stock Performance
The business has a 50-day simple moving average of C$0.15 and a 200-day simple moving average of C$0.10. The company has a market cap of C$27.44 million, a price-to-earnings ratio of -15.75 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- 3 Warren Buffett Stocks to Buy Now
- Kimberly-Clark: A Regal Opportunity in This Dividend King
- How to Calculate Stock Profit
- 5 Stocks With Above-Market Yields Just Raised Payments Further
- What is the Dogs of the Dow Strategy? Overview and Examples
- Arista Networks’ Stock Plunge: Buying Opportunity for Investors?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
